NCT04558463.

Study name	The effectivity and safety of favipiravir compared to oseltamivir as adjuvant therapy for COVID‐19
Methods	Open‐label RCT
Participants	Adult COVID‐19 patients with mild, moderate, and severe symptoms
Interventions	Favipiravir, oseltamivir
Outcomes	Primary Clinical radiologic changes: changes in lung infiltrate in chest X‐ray and/or ground‐glass opacity in chest CT scan after 14 days of follow‐up. This outcome measure will be displayed as improvement/no changes/deterioration of radiologic examination results. Time frame: 14 days Percentage of RT‐PCR test conversion: conversion of RT‐PCR swab result from positive to negative at the end of 14 days of follow‐up. This outcome measure will be displayed as conversion OR no conversion. Time frame: 14 days Secondary (time frame for all secondary outcomes: 14 days) Adverse events: mild to moderate adverse events, serious adverse events such as severe allergy and increased transaminase enzyme > 3x normal limit Hospital length of stay (LOS): days of hospitalization from the first dose of intervention Case fatality rate (CFR): calculated from mortality rate during hospital admission
Starting date	16 April 2020
Contact information	Contact: Dante S Harbuwono, MD, PhD +62213907703 dante.saksono@ui.ac.id Contact: Cleopas M Rumende, MD, PhD +62 21 3149704 rumende_martin@yahoo.com
Notes